Urticaria: A comprehensive review
| Autor: | Katherine Baquerizo, Ali Alikhan, Jonathan A. Bernstein, Camila Antia, Abraham Korman |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Allergy
medicine.medical_specialty Special populations Omalizumab Dermatology law.invention 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Randomized controlled trial Quality of life Continuing medical education law immune system diseases parasitic diseases Epidemiology Health care Medicine skin and connective tissue diseases Intensive care medicine Chronic urticaria Disease burden Asthma Angioedema business.industry medicine.disease Work-up 030228 respiratory system Autologous serum skin test medicine.symptom business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 79:599-614 |
| ISSN: | 0190-9622 |
| Popis: | Second-generation antihistamines are considered first-line agents in the treatment of chronic urticaria because of their safety and efficacy profile. Some patients require higher doses of H1 antihistamines alone or in combination with other classes of medications, including H2 antihistamines, leukotriene receptor antagonists, or first-generation H1 antihistamines. One major therapeutic advance has been omalizumab, a humanized monoclonal anti–immunoglobulin E that was recently approved by the US Food and Drug Administration for the treatment of chronic urticaria that is unresponsive to H1 antagonists. In addition, the second article in this continuing medical education series outlines several evidence-based alternative treatments for urticaria and the differences in recommendations between 2 major consensus groups (the European Academy of Allergy and Clinical Immunology/World Allergy Organization and the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect